A Multicenter Phase II Study of Second‐Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First‐Line Sorafenib Monotherapy

LESSONS LEARNED: For patients with advanced hepatocellular carcinoma after failure of first‐line sorafenib monotherapy, second‐line axitinib provides modest efficacy with tolerable toxicity. The discrepant tumor responses and survival outcomes in trials using axitinib as salvage therapy highlight th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Lin, Zhong‐Zhe, Chen, Bang‐Bin, Hung, Yi‐Ping, Huang, Po‐Hsiang, Shen, Ying‐Chun, Shao, Yu‐Yun, Hsu, Chih‐Hung, Cheng, Ann‐Lii, Lee, Rheun‐Chuan, Chao, Yee, Hsu, Chiun
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485356/
https://ncbi.nlm.nih.gov/pubmed/32271494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0143
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items